Summarized by Masters of Longevity from Youtube - Dr. Stan Bradfield.
A video essay examining why a major trial of an Lp(a)-lowering drug missed its primary cardiovascular goal and what questions that raises for future research and patient care.
Key Takeaways
- The Horizon trial enrolled 8,323 patients with prior cardiovascular disease and Lp(a) ≥149 nmol/L and randomized them to pelacarsen or placebo.
- Pelacarsen previously reduced Lp(a) by roughly 70–80% in earlier studies but did not lower major cardiovascular events in this trial.
- Full trial results were pending public release, and the sponsor announced the primary endpoint was not met across the whole population.
